Abstract
Medication-related osteonecrosis of the jaw (MRONJ), a severe side effect caused by antiresorptive antiangiogenic medication, particularly bisphosphonates (BPs), has become a challenging disease with serious and profound effects on the physical and mental health of patients. Although it occurs with high frequency and is harmful, the exact mechanism of MRONJ remains unknown, and systematic and targeted approaches are still lacking. Maxillofacial surgeons focus on the etiology of osteonecrosis in the mandible and maxilla as well as the appropriate oral interventions for high-risk patients. Adequate nursing care and pharmacotherapy management are also crucial. This review provides a current overview of the clinicopathologic feature and research of MRONJ caused by BPs, with an emphasis on the potential mechanisms and current therapy and prevention strategies of the disease. We are of the opinion that an in-depth comprehension of the mechanisms underlying MRONJ will facilitate the development of more precise and efficacious therapeutic approaches, resulting in enhanced clinical outcomes for patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Not applicable.
References
Aghaloo TL, Kang B, Sung EC et al (2011) Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. J Bone Miner Res 26(8):1871–1882. https://doi.org/10.1002/jbmr.379
Aguirre JI, Castillo EJ, Kimmel DB (2021a) Biologic and pathologic aspects of osteocytes in the setting of medication-related osteonecrosis of the jaw (MRONJ). Bone 153:116168. https://doi.org/10.1016/j.bone.2021.116168
Aguirre JI, Castillo EJ, Kimmel DB (2021b) Preclinical models of medication-related osteonecrosis of the jaw (MRONJ). Bone 153:116184. https://doi.org/10.1016/j.bone.2021.116184
Allegra A, Alonci A, Penna G et al (2010) Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws. Acta Haematol 124(2):79–85. https://doi.org/10.1159/000313787
Allen MR, Burr DB (2008) Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 66(5):987–994. https://doi.org/10.1016/j.joms.2008.01.038
Awan AA, Hutton B, Hilton J et al (2019) De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 176(3):507–517. https://doi.org/10.1007/s10549-019-05265-1
Barbosa JS, Almeida Paz FA, Braga SS (2021) Bisphosphonates, old friends of bones and new trends in clinics. J Med Chem 64(3):1260–1282. https://doi.org/10.1021/acs.jmedchem.0c01292
Bashutski JD, Eber RM, Kinney JS et al (2010) Teriparatide and osseous regeneration in the oral cavity. N Engl J Med 363(25):2396–2405. https://doi.org/10.1056/NEJMoa1005361
Bedogni A, Blandamura S, Lokmic Z et al (2008) Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105(3):358–364. https://doi.org/10.1016/j.tripleo.2007.08.040
Bedogni A, Saia G, Bettini G et al (2011) Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis. Oral Oncol 47(5):420–424. https://doi.org/10.1016/j.oraloncology.2011.02.024
Bermúdez-Bejarano EB, Serrera-Figallo M, Gutiérrez-Corrales A et al (2017) Prophylaxis and antibiotic therapy in management protocols of patients treated with oral and intravenous bisphosphonates. J Clin Exp Dent 9(1):e141–e149. https://doi.org/10.4317/jced.53372
Bianchi SD, Scoletta M, Cassione FB, Migliaretti G, Mozzati M (2007) Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104(2):249–258. https://doi.org/10.1016/j.tripleo.2007.01.040
Bock O, Boerst H, Thomasius FE et al (2007) Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact 7(2):144–148
Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelanat F (1983) Renal failure associated with intravenous diphosphonates. Lancet 1(8322):471. https://doi.org/10.1016/s0140-6736(83)91465-4
Caplan L, Pittman CB, Zeringue AL et al (2010) An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy. Mayo Clin Proc 85(4):341–348. https://doi.org/10.4065/mcp.2009.0492
Carlson ER, Basile JD (2009) The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67(5 Suppl):85–95. https://doi.org/10.1016/j.joms.2009.01.006
Carreira AC, Lojudice FH, Halcsik E, Navarro RD, Sogayar MC, Granjeiro JM (2014) Bone morphogenetic proteins: facts, challenges, and future perspectives. J Dent Res 93(4):335–345. https://doi.org/10.1177/0022034513518561
Chin KY, Ekeuku SO, Trias A (2022) The role of geranylgeraniol in managing bisphosphonate-related osteonecrosis of the jaw. Front Pharmacol 13:878556. https://doi.org/10.3389/fphar.2022.878556
Chow L, Johnson V, Impastato R, Coy J, Strumpf A, Dow S (2020) Antibacterial activity of human mesenchymal stem cells mediated directly by constitutively secreted factors and indirectly by activation of innate immune effector cells. Stem Cells Transl Med 9(2):235–249. https://doi.org/10.1002/sctm.19-0092
Cicciù M, Herford AS, Juodžbalys G, Stoffella E (2012) Recombinant human bone morphogenetic protein type 2 application for a possible treatment of bisphosphonates-related osteonecrosis of the jaw. J Craniofac Surg 23(3):784–788. https://doi.org/10.1097/SCS.0b013e31824dbdd4
Clézardin P, Coleman R, Puppo M et al (2021) Bone metastasis: mechanisms, therapies, and biomarkers. Physiol Rev 101(3):797–855. https://doi.org/10.1152/physrev.00012.2019
Coleman R (2011) The use of bisphosphonates in cancer treatment. Ann N Y Acad Sci 1218:3–14. https://doi.org/10.1111/j.1749-6632.2010.05766.x
Colón-Emeric CS, Mesenbrink P, Lyles KW et al (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25(1):91–97. https://doi.org/10.1359/jbmr.090704
de Sousa Ferreira VC, Lopes AP, Alves NM et al (2021) Bisphosphonate-related osteonecrosis induced change in alveolar bone architecture in rats with participation of Wnt signaling. Clin Oral Investig 25(2):673–682. https://doi.org/10.1007/s00784-020-03551-7
Di Fede O, Panzarella V, Mauceri R et al (2018) The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention. Biomed Res Int 2018:2684924. https://doi.org/10.1155/2018/2684924
Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83(9):1032–1045. https://doi.org/10.4065/83.9.1032
Escudier B, Porta C, Schmidinger M et al (2019) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 30(5):706–720. https://doi.org/10.1093/annonc/mdz056
Feng X, Teitelbaum SL (2013) Osteoclasts: new insights. Bone Res 1(1):11–26. https://doi.org/10.4248/br201301003
Fornaini C, Cella L, Oppici A et al (2017) Laser and platelet-rich plasma to treat medication-related osteonecrosis of the jaws (MRONJ): a case report. Laser Ther 26(3):223–227. https://doi.org/10.5978/islsm.17-CR-04
Francisconi CF, Vieira AE, Azevedo MCS et al (2018) RANKL triggers treg-mediated immunoregulation in inflammatory osteolysis. J Dent Res 97(8):917–927. https://doi.org/10.1177/0022034518759302
Franco-Pretto E, Pacheco M, Moreno A, Messa O, Gnecco J (2014) Bisphosphonate-induced osteonecrosis of the jaws: clinical, imaging, and histopathology findings. Oral Surg Oral Med Oral Pathol Oral Radiol 118(4):408–417. https://doi.org/10.1016/j.oooo.2014.04.017
Fraunfelder FW, Fraunfelder FT, Jensvold B (2003) Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 135(2):219–222. https://doi.org/10.1016/s0002-9394(02)01840-8
French DD, Margo CE (2008) Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina 28(6):889–893. https://doi.org/10.1097/IAE.0b013e31816576ef
Gatti D, Rossini M, Viapiana O, Idolazzi L, Adami S (2013) Clinical development of neridronate: potential for new applications. Ther Clin Risk Manag 9:139–147. https://doi.org/10.2147/tcrm.S35788
Gau YC, Yeh TJ, Hsu CM, Hsiao SY, Hsiao HH (2022) Pathogenesis and treatment of myeloma-related bone disease. Int J Mol Sci. https://doi.org/10.3390/ijms23063112
Giusti A, Hamdy NA, Papapoulos SE (2010) Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 47(2):169–180. https://doi.org/10.1016/j.bone.2010.05.019
Gkouveris I, Soundia A, Gouveris P, Zouki D, Hadaya D, Tetradis S (2022) Macrophage involvement in medication-related osteonecrosis of the jaw (MRONJ): a comprehensive, short review. Cancers (basel). https://doi.org/10.3390/cancers14020330
Goker F, Grecchi E, Grecchi F, Francetti L, Del Fabbro M (2021) Treatment of medication-related osteonecrosis of the jaw (MRONJ). A systematic review. Eur Rev Med Pharmacol Sci 25(6):2662–2673. https://doi.org/10.26355/eurrev_202103_25430
Gong X, Yu W, Zhao H, Su J, Sheng Q (2017) Skeletal site-specific effects of zoledronate on in vivo bone remodeling and in vitro bmscs osteogenic activity. Sci Rep 7:36129. https://doi.org/10.1038/srep36129
Govaerts D, Piccart F, Ockerman A, Coropciuc R, Politis C, Jacobs R (2020) Adjuvant therapies for MRONJ: a systematic review. Bone 141:115676. https://doi.org/10.1016/j.bone.2020.115676
Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V (2010) Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 341:c4444. https://doi.org/10.1136/bmj.c4444
Hadaya D, Soundia A, Freymiller E et al (2018) Nonsurgical management of medication-related osteonecrosis of the jaws using local wound care. J Oral Maxillofac Surg 76(11):2332–2339. https://doi.org/10.1016/j.joms.2018.05.025
Hadaya D, Soundia A, Gkouveris I, Dry SM, Aghaloo TL, Tetradis S (2019) Development of medication-related osteonecrosis of the jaw after extraction of teeth with experimental periapical disease. J Oral Maxillofac Surg 77(1):71–86. https://doi.org/10.1016/j.joms.2018.08.010
Hagelauer N, Pabst AM, Ziebart T, Ulbrich H, Walter C (2015) In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes. Clin Oral Investig 19(1):139–148. https://doi.org/10.1007/s00784-014-1219-0
Halasy-Nagy JM, Rodan GA, Reszka AA (2001) Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 29(6):553–559. https://doi.org/10.1016/s8756-3282(01)00615-9
Hallmer F, Bjørnland T, Andersson G, Becktor JP, Kristoffersen AK, Enersen M (2017) Bacterial diversity in medication-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 123(4):436–444. https://doi.org/10.1016/j.oooo.2016.11.011
Hasegawa T, Hayashida S, Kondo E et al (2019) Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study. Osteoporos Int 30(1):231–239. https://doi.org/10.1007/s00198-018-4746-8
Hoefert S, Schmitz I, Tannapfel A, Eufinger H (2010) Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Investig 14(3):271–284. https://doi.org/10.1007/s00784-009-0300-6
Hu D, Colnot C, Marcucio RS (2008) Effect of bone morphogenetic protein signaling on development of the jaw skeleton. Dev Dyn 237(12):3727–3737. https://doi.org/10.1002/dvdy.21781
Iguchi K (2012) Effect of bisphosphonates on anticancer activity in prostate cancer cells. Yakugaku Zasshi 132(9):1025–1030. https://doi.org/10.1248/yakushi.132.1025
Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS (2004) Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 25(18):4105–4115. https://doi.org/10.1016/j.biomaterials.2003.11.024
Itoh F, Aoyagi S, Furihata-Komatsu H et al (2003) Clodronate stimulates osteoblast differentiation in ST2 and MC3T3-E1 cells and rat organ cultures. Eur J Pharmacol 477(1):9–16. https://doi.org/10.1016/j.ejphar.2003.08.011
Kalyan S, Quabius ES, Wiltfang J, Mönig H, Kabelitz D (2013) Can peripheral blood γδ T cells predict osteonecrosis of the jaw? An immunological perspective on the adverse drug effects of aminobisphosphonate therapy. J Bone Miner Res 28(4):728–735. https://doi.org/10.1002/jbmr.1769
Kaneko J, Okinaga T, Hikiji H et al (2018) Zoledronic acid exacerbates inflammation through M1 macrophage polarization. Inflamm Regen 38:16. https://doi.org/10.1186/s41232-018-0074-9
Kang B, Cheong S, Chaichanasakul T et al (2013) Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice. J Bone Miner Res 28(7):1631–1640. https://doi.org/10.1002/jbmr.1894
Kates SL, Ackert-Bicknell CL (2016) How do bisphosphonates affect fracture healing? Injury 47(0 1):S65–S68. https://doi.org/10.1016/s0020-1383(16)30015-8
Kaur K, Kanayama K, Wu QQ, Gumrukcu S, Nishimura I, Jewett A (2022) Zoledronic acid mediated differential activation of NK cells in different organs of WT and Rag2(-/-) mice; stark differences between the bone marrow and gingivae. Cell Immunol 375:104526. https://doi.org/10.1016/j.cellimm.2022.104526
Khan AA, Morrison A, Hanley DA et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30(1):3–23. https://doi.org/10.1002/jbmr.2405
Kim JW, Landayan ME, Lee JY et al (2016) Role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw. Clin Oral Investig 20(8):2251–2258. https://doi.org/10.1007/s00784-016-1718-2
Kim S, Mun S, Shin W, Han K, Kim MY (2022) Identification of potentially pathogenic variants associated with recurrence in medication-related osteonecrosis of the jaw (MRONJ) patients using whole-exome sequencing. J Clin Med. https://doi.org/10.3390/jcm11082145
Kitagawa Y, Ohga N, Asaka T et al (2019) Imaging modalities for drug-related osteonecrosis of the jaw (3), Positron emission tomography imaging for the diagnosis of medication-related osteonecrosis of the jaw. Jpn Dent Sci Rev 55(1):65–70. https://doi.org/10.1016/j.jdsr.2018.12.001
Kozlowska AK, Topchyan P, Kaur K et al (2017) Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs. J Cancer 8(4):537–554. https://doi.org/10.7150/jca.15989
Kravets I (2018) Paget’s disease of bone: diagnosis and treatment. Am J Med 131(11):1298–1303. https://doi.org/10.1016/j.amjmed.2018.04.028
Krishnan A, Arslanoglu A, Yildirm N, Silbergleit R, Aygun N (2009) Imaging findings of bisphosphonate-related osteonecrosis of the jaw with emphasis on early magnetic resonance imaging findings. J Comput Assist Tomogr 33(2):298–304. https://doi.org/10.1097/RCT.0b013e31817e4986
Kuiper JW, Forster C, Sun C, Peel S, Glogauer M (2012) Zoledronate and pamidronate depress neutrophil functions and survival in mice. Br J Pharmacol 165(2):532–539. https://doi.org/10.1111/j.1476-5381.2011.01592.x
Kuroshima S, Al-Omari FA, Sasaki M, Sawase T (2022) Medication-related osteonecrosis of the jaw: a literature review and update. Genesis 60(8–9):e23500. https://doi.org/10.1002/dvg.23500
Leali PT, Balsano M, Maestretti G et al (2017) Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study. Clin Cases Miner Bone Metab 14(2):153–156. https://doi.org/10.11138/ccmbm/2017.14.1.153
Lemound J, Muecke T, Zeller AN, Lichtenstein J, Eckardt A, Gellrich NC (2018) Nasolabial flap improves healing in medication-related osteonecrosis of the jaw. J Oral Maxillofac Surg 76(4):877–885. https://doi.org/10.1016/j.joms.2017.09.021
Li H, Xiao Z, Quarles LD, Li W (2021) Osteoporosis: mechanism, molecular target and current status on drug development. Curr Med Chem 28(8):1489–1507. https://doi.org/10.2174/0929867327666200330142432
Li JW, Wang JY, Yu RQ, Huo L, Zheng LW (2022a) Expression of angiogenic markers in jawbones and femur in a rat model treated with zoledronic acid. BMC Res Notes 15(1):12. https://doi.org/10.1186/s13104-021-05900-5
Li X, Xu R, Ye JX, Yuan FL (2022b) Suppression of bone remodeling associated with long-term bisphosphonate treatment is mediated by microRNA-30a-5p. Bioengineered 13(4):9741–9753. https://doi.org/10.1080/21655979.2022.2060584
Lichtman MK, Otero-Vinas M, Falanga V (2016) Transforming growth factor beta (TGF-β) isoforms in wound healing and fibrosis. Wound Repair Regen 24(2):215–222. https://doi.org/10.1111/wrr.12398
Longo F, Guida A, Aversa C et al (2014) Platelet rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw: personal experience and review of the literature. Int J Dent 2014:298945. https://doi.org/10.1155/2014/298945
Lopez-Jornet P, Sanchez Perez A, Amaral Mendes R, Tobias A (2016) Medication-related osteonecrosis of the jaw: Is autologous platelet concentrate application effective for prevention and treatment? A systematic review. J Craniomaxillofac Surg 44(8):1067–1072. https://doi.org/10.1016/j.jcms.2016.05.004
Lotz EM, Lohmann CH, Boyan BD, Schwartz Z (2020) Bisphosphonates inhibit surface-mediated osteogenesis. J Biomed Mater Res A 108(8):1774–1786. https://doi.org/10.1002/jbm.a.36944
Marom R, Rabenhorst BM, Morello R (2020) Osteogenesis imperfecta: an update on clinical features and therapies. Eur J Endocrinol 183(4):R95-r106. https://doi.org/10.1530/eje-20-0299
Maruotti N, Corrado A, Neve A, Cantatore FP (2012) Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol 68(7):1013–1018. https://doi.org/10.1007/s00228-012-1216-7
Mathov I, Plotkin LI, Sgarlata CL, Leoni J, Bellido T (2001) Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro. J Bone Miner Res 16(11):2050–2056. https://doi.org/10.1359/jbmr.2001.16.11.2050
Mijiritsky E, Assaf HD, Kolerman R, Mangani L, Ivanova V, Zlatev S (2022) Autologous platelet concentrates (APCs) for hard tissue regeneration in oral implantology, sinus floor elevation, peri-implantitis, socket preservation, and medication-related osteonecrosis of the jaw (MRONJ): a literature review. Biology (basel). https://doi.org/10.3390/biology11091254
Miller SC, Jee WS, Kimmel DB, Woodbury L (1977) Ethane-1-hydroxy-1, 1-diphosphonate (EHDP) effects on incorporation and accumulation of osteoclast nuclei. Calcif Tissue Res 22(3):243–252. https://doi.org/10.1007/bf02010363
Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE (2005) Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20(12):2105–2115. https://doi.org/10.1359/jbmr.050817
Minisola S, Pepe J, Piemonte S, Cipriani C (2015) The diagnosis and management of hypercalcaemia. BMJ 350:h2723. https://doi.org/10.1136/bmj.h2723
Movila A, Mawardi H, Nishimura K et al (2016) Possible pathogenic engagement of soluble Semaphorin 4D produced by γδT cells in medication-related osteonecrosis of the jaw (MRONJ). Biochem Biophys Res Commun 480(1):42–47. https://doi.org/10.1016/j.bbrc.2016.10.012
Mu H, Pang Y, Liu L, Liu J, Liu C (2023) Clinical values of serum Semaphorin 4D (Sema4D) in medication-related osteonecrosis of the jaw. Eur J Med Res 28(1):140. https://doi.org/10.1186/s40001-023-01095-6
Murakami H, Takahashi N, Sasaki T et al (1995) A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 17(2):137–144. https://doi.org/10.1016/s8756-3282(95)00150-6
Nakashima T, Hayashi M, Fukunaga T et al (2011) Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17(10):1231–1234. https://doi.org/10.1038/nm.2452
Nicolatou-Galitis O, Schiødt M, Mendes RA et al (2019) Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol 127(2):117–135. https://doi.org/10.1016/j.oooo.2018.09.008
Nifosì G, Nifosì L, Nifosì AF (2021) Mesenchymal stem cells in the treatment of osteonecrosis of the jaw. J Korean Assoc Oral Maxillofac Surg 47(2):65–75. https://doi.org/10.5125/jkaoms.2021.47.2.65
Ogura I, Minami Y, Ono J et al (2021) CBCT imaging and histopathological characteristics of osteoradionecrosis and medication-related osteonecrosis of the jaw. Imaging Sci Dent 51(1):73–80. https://doi.org/10.5624/isd.20200230
Ohbayashi Y, Nakai F, Iwasaki A et al (2017) The utility of bone scintigraphy in the assessment of mandibular metabolism during long-term bisphosphonate administration. Odontology 105(3):382–390. https://doi.org/10.1007/s10266-016-0279-9
Ohbayashi Y, Nakai F, Iwasaki A et al (2019) Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (6), assessment of mandibular metabolism due to long-term administration of an anti-resorptive agent by bone scintigraphy (secondary publication). Jpn Dent Sci Rev 55(1):51–57. https://doi.org/10.1016/j.jdsr.2018.11.002
Ohishi T, Matsuyama Y (2018) Minodronate for the treatment of osteoporosis. Ther Clin Risk Manag 14:729–739. https://doi.org/10.2147/tcrm.S149236
On SW, Cho SW, Byun SH, Yang BE (2021) Various therapeutic methods for the treatment of medication-related osteonecrosis of the jaw (MRONJ) and their limitations: a narrative review on new molecular and cellular therapeutic approaches. Antioxidants (basel). https://doi.org/10.3390/antiox10050680
Ono T, Okamoto K, Nakashima T et al (2016) IL-17-producing γδ T cells enhance bone regeneration. Nat Commun 7:10928. https://doi.org/10.1038/ncomms10928
Ono N, Balani DH, Kronenberg HM (2019) Stem and progenitor cells in skeletal development. Curr Top Dev Biol 133:1–24. https://doi.org/10.1016/bs.ctdb.2019.01.006
Orecchioni M, Ghosheh Y, Pramod AB, Ley K (2019) Macrophage polarization: different gene signatures in M1(LPS+) vs. classically and M2(LPS-) vs. alternatively activated macrophages. Front Immunol 10:1084. https://doi.org/10.3389/fimmu.2019.01084
Oteri G, Allegra A, Bellomo G et al (2008) Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration. Cytokine 43(2):103–104. https://doi.org/10.1016/j.cyto.2008.05.010
Papapetrou PD (2009) Bisphosphonate-associated adverse Events. Hormones (athens) 8(2):96–110. https://doi.org/10.14310/horm.2002.1226
Paschalidi P, Gkouveris I, Soundia A et al (2021) The role of M1 and M2 macrophage polarization in progression of medication-related osteonecrosis of the jaw. Clin Oral Investig 25(5):2845–2857. https://doi.org/10.1007/s00784-020-03602-z
Patntirapong S, Poolgesorn M (2018) Alteration of macrophage viability, differentiation, and function by bisphosphonates. Oral Dis 24(7):1294–1302. https://doi.org/10.1111/odi.12908
Pedersen AB, Nørholt SE, Rejnmark L, Langdahl B, Starch-Jensen T, Sørensen HT (2023) Genome-wide association study of osteonecrosis of the jaw in Danish patients receiving antiresorptive therapy for osteoporosis: a case-control study. Bone Rep 18:101648. https://doi.org/10.1016/j.bonr.2022.101648
Phal PM, Myall RW, Assael LA, Weissman JL (2007) Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. AJNR Am J Neuroradiol 28(6):1139–1145. https://doi.org/10.3174/ajnr.A0518
Preidl RHM, Amann K, Weber M et al (2021) Lineage-associated connexin 43 expression in bisphosphonate-exposed rat bones. J Craniomaxillofac Surg 49(8):738–747. https://doi.org/10.1016/j.jcms.2021.02.010
Ramaglia L, Guida A, Iorio-Siciliano V, Cuozzo A, Blasi A, Sculean A (2018) Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol. Clin Oral Investig 22(2):597–615. https://doi.org/10.1007/s00784-017-2325-6
Reid IR (2020) A broader strategy for osteoporosis interventions. Nat Rev Endocrinol 16(6):333–339. https://doi.org/10.1038/s41574-020-0339-7
Reid IR (2022) Extensive expertise in endocrinology: osteoporosis management. Eur J Endocrinol 187(4):R65-r80. https://doi.org/10.1530/eje-22-0574
Reid IR, Green JR, Lyles KW et al (2020) Zoledronate. Bone 137:115390. https://doi.org/10.1016/j.bone.2020.115390
Ristow O, Gerngroß C, Schwaiger M et al (2014) Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis? J Oral Maxillofac Surg 72(5):903–910. https://doi.org/10.1016/j.joms.2013.11.005
Ristow O, Rückschloß T, Müller M et al (2019) Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study. J Craniomaxillofac Surg 47(3):491–499. https://doi.org/10.1016/j.jcms.2018.12.014
Roato I, Mauceri R, Notaro V, Genova T, Fusco V, Mussano F (2023) Immune dysfunction in medication-related osteonecrosis of the jaw. Int J Mol Sci. https://doi.org/10.3390/ijms24097948
Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12(20):6222s–6230s. https://doi.org/10.1158/1078-0432.Ccr-06-0843
Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FP (2010) Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 16(27):2950–2960. https://doi.org/10.2174/138161210793563635
Rollason V, Laverrière A, MacDonald LC, Walsh T, Tramèr MR, Vogt-Ferrier NB (2016) Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ). Cochrane Database Syst Rev 2(2):Cd008455. https://doi.org/10.1002/14651858.CD008455.pub2
Ruggiero SL, Dodson TB, Fantasia J et al (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update. J Oral Maxillofac Surg 72(10):1938–1956. https://doi.org/10.1016/j.joms.2014.04.031
Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg 80(5):920–943. https://doi.org/10.1016/j.joms.2022.02.008
Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19(6):733–759. https://doi.org/10.1007/s00198-007-0540-8
Russmueller G, Seemann R, Weiss K et al (2016) The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection. Sci Rep 6:31604. https://doi.org/10.1038/srep31604
Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94(19):1458–1468. https://doi.org/10.1093/jnci/94.19.1458
Sacco R, Sacco N, Hamid U, Ali SH, Singh M, Blythe JSJ (2018) Microsurgical reconstruction of the jaws using vascularised free flap technique in patients with medication-related osteonecrosis: a systematic review. Biomed Res Int 2018:9858921. https://doi.org/10.1155/2018/9858921
Sacco R, Shah S, Leeson R et al (2020) Osteonecrosis and osteomyelitis of the jaw associated with tumour necrosis factor-alpha (TNF-α) inhibitors: a systematic review. Br J Oral Maxillofac Surg 58(1):25–33. https://doi.org/10.1016/j.bjoms.2019.09.023
Sacco R, Akintola O, Sacco N et al (2023) The use of human amniotic membrane (hAM) as a treatment strategy of medication-related osteonecrosis of the jaw (MRONJ): a systematic review and meta-analysis of the literature. Medicina (kaunas) 59(5):10. https://doi.org/10.3390/medicina59050968
Sanna G, Preda L, Bruschini R et al (2006) Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol 17(10):1512–1516. https://doi.org/10.1093/annonc/mdl163
Scheller EL, Hankenson KD, Reuben JS, Krebsbach PH (2011) Zoledronic acid inhibits macrophage SOCS3 expression and enhances cytokine production. J Cell Biochem 112(11):3364–3372. https://doi.org/10.1002/jcb.23267
Senel FC, Saracoglu Tekin U, Durmus A, Bagis B (2007) Severe osteomyelitis of the mandible associated with the use of non-nitrogen-containing bisphosphonate (disodium clodronate): report of a case. J Oral Maxillofac Surg 65(3):562–565. https://doi.org/10.1016/j.joms.2006.10.043
Shane E, Burr D, Abrahamsen B et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29(1):1–23. https://doi.org/10.1002/jbmr.1998
Shapouri-Moghaddam A, Mohammadian S, Vazini H et al (2018) Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol 233(9):6425–6440. https://doi.org/10.1002/jcp.26429
Shu HS, Liu YL, Tang XT et al (2021) Tracing the skeletal progenitor transition during postnatal bone formation. Cell Stem Cell 28(12):2122-2136.e3. https://doi.org/10.1016/j.stem.2021.08.010
Silveira FM, Etges A, Correa MB, Vasconcelos AC (2016) Microscopic evaluation of the effect of oral microbiota on the development of bisphosphonate-related osteonecrosis of the jaws in rats. J Oral Maxillofac Res 7(4):e3. https://doi.org/10.5037/jomr.2016.7403
Sim IW, Borromeo GL, Tsao C et al (2020) Teriparatide Promotes Bone Healing In Medication-Related Osteonecrosis Of The Jaw: A Placebo-Controlled. Randomized Trial J Clin Oncol 38(26):2971–2980. https://doi.org/10.1200/jco.19.02192
Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC (2009) Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol 45(2):164–172. https://doi.org/10.1016/j.oraloncology.2008.04.013
Soutome S, Hayashida S, Funahara M et al (2018) Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: is tooth extraction a risk factor? PLoS ONE 13(7):e0201343. https://doi.org/10.1371/journal.pone.0201343
Soutome S, Otsuru M, Hayashida S et al (2021) Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients. Sci Rep 11(1):17226. https://doi.org/10.1038/s41598-021-96480-8
Stefanik D, Sarin J, Lam T, Levin L, Leboy PS, Akintoye SO (2008) Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate. Oral Dis 14(5):465–471. https://doi.org/10.1111/j.1601-0825.2007.01402.x
Stein M, Keshav S, Harris N, Gordon S (1992) Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 176(1):287–292. https://doi.org/10.1084/jem.176.1.287
Stockmann P, Hinkmann FM, Lell MM et al (2010) Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clin Oral Investig 14(3):311–317. https://doi.org/10.1007/s00784-009-0293-1
Taş Ozyurtseven B, Serin I, Nursal AF, Pehlivan S, Pehlivan M (2021) Medication-related osteonecrosis of the jaw (MRONJ) and eNOS Polymorphisms in multiple myeloma patients: a single center experience. BMC Oral Health 21(1):272. https://doi.org/10.1186/s12903-021-01634-9
Thompson K, Rogers MJ, Coxon FP, Crockett JC (2006) Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 69(5):1624–1632. https://doi.org/10.1124/mol.105.020776
Toro LF, de Mello-Neto JM, Santos F et al (2019) Application of autologous platelet-rich plasma on tooth extraction site prevents occurence of medication-related osteonecrosis of the jaws in rats. Sci Rep 9(1):22. https://doi.org/10.1038/s41598-018-37063-y
Torres SR, Chen CS, Leroux BG et al (2015) Mandibular inferior cortical bone thickness on panoramic radiographs in patients using bisphosphonates. Oral Surg Oral Med Oral Pathol Oral Radiol 119(5):584–592. https://doi.org/10.1016/j.oooo.2015.02.005
van Beek E, Hoekstra M, van de Ruit M, Löwik C, Papapoulos S (1994) Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 9(12):1875–1882. https://doi.org/10.1002/jbmr.5650091206
Van Poznak C, Somerfield MR, Barlow WE et al (2017) Role of bone-modifying agents in metastatic breast cancer: an american society of clinical oncology-cancer care ontario focused guideline update. J Clin Oncol 35(35):3978–3986. https://doi.org/10.1200/jco.2017.75.4614
Varenna M, Bertoldo F, Di Monaco M, Giusti A, Martini G, Rossini M (2013) Safety profile of drugs used in the treatment of osteoporosis: a systematical review of the literature. Reumatismo 65(4):143–166. https://doi.org/10.4081/reumatismo.2013.143
Varma R, Aronow WS, Basis Y et al (2008) Relation of bone mineral density to frequency of coronary heart disease. Am J Cardiol 101(8):1103–1104. https://doi.org/10.1016/j.amjcard.2007.12.013
Viereck V, Emons G, Lauck V et al (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291(3):680–686. https://doi.org/10.1006/bbrc.2002.6510
Vrdoljak E, Rini B, Schmidinger M et al (2013) Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. Anticancer Drugs 24(5):431–440. https://doi.org/10.1097/CAD.0b013e328360335f
Weinstein RS, Roberson PK, Manolagas SC (2009) Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 360(1):53–62. https://doi.org/10.1056/NEJMoa0802633
Wilde F, Heufelder M, Winter K et al (2011) The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 111(2):153–163. https://doi.org/10.1016/j.tripleo.2010.04.015
Woelber JP, Fleiner J, Rau J, Ratka-Krüger P, Hannig C (2018) Accuracy and usefulness of CBCT in periodontology: a systematic review of the literature. Int J Periodontics Restorative Dent 38(2):289–297. https://doi.org/10.11607/prd.2751
Wood J, Bonjean K, Ruetz S et al (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302(3):1055–1061. https://doi.org/10.1124/jpet.102.035295
Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O’Brien CA (2011) Matrix-embedded cells control osteoclast formation. Nat Med 17(10):1235–1241. https://doi.org/10.1038/nm.2448
Yamazaki Y, Kitagawa Y, Hata H et al (2010) Use of FDG PET to evaluate hyperbaric oxygen therapy for bisphosphonate-related osteonecrosis of the jaw. Clin Nucl Med 35(8):590–591. https://doi.org/10.1097/RLU.0b013e3181e4df11
Yang M, Yu X (2020) Management of bone metastasis with intravenous bisphosphonates in breast cancer: a systematic review and meta-analysis of dosing frequency. Support Care Cancer 28(6):2533–2540. https://doi.org/10.1007/s00520-020-05355-7
Yang G, Singh S, Chen Y et al (2019) Pharmacogenomics of osteonecrosis of the jaw. Bone 124:75–82. https://doi.org/10.1016/j.bone.2019.04.010
Yarom N, Shapiro CL, Peterson DE et al (2019) Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. J Clin Oncol 37(25):2270–2290. https://doi.org/10.1200/jco.19.01186
Yuan A, Munz A, Reinert S, Hoefert S (2019) Gingival fibroblasts and medication-related osteonecrosis of the jaw: results by real-time and wound healing in vitro assays. J Craniomaxillofac Surg 47(9):1464–1474. https://doi.org/10.1016/j.jcms.2019.06.004
Zhang Q, Atsuta I, Liu S et al (2013) IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws. Clin Cancer Res 19(12):3176–3188. https://doi.org/10.1158/1078-0432.Ccr-13-0042
Zheng Y, Dong X, Chen S et al (2023) Low-level laser therapy prevents medication-related osteonecrosis of the jaw-like lesions via IL-1RA-mediated primary gingival wound healing. BMC Oral Health 23(1):14. https://doi.org/10.1186/s12903-022-02678-1
Zhu W, Xu R, Du J et al (2019) Zoledronic acid promotes TLR-4-mediated M1 macrophage polarization in bisphosphonate-related osteonecrosis of the jaw. Faseb j 33(4):5208–5219. https://doi.org/10.1096/fj.201801791RR
Ziebart T, Koch F, Klein MO et al (2011) Geranylgeraniol—a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw. Oral Oncol 47(3):195–201. https://doi.org/10.1016/j.oraloncology.2010.12.003
Zirk M, Wenzel C, Buller J, Zöller JE, Zinser M, Peters F (2019) Microbial diversity in infections of patients with medication-related osteonecrosis of the jaw. Clin Oral Investig 23(5):2143–2151. https://doi.org/10.1007/s00784-018-2655-z
Acknowledgements
This work was financially supported by the National Natural Science Foundation of China (Grant No. 82103460).
Author information
Authors and Affiliations
Contributions
AJ: Conceptualization; writing—original draft. ZZ: Conceptualization, Funding acquisition, Writing—review and editing. XQ: Conceptualization, Writing—reviewing and Editing. QG: Conceptualization, Funding acquisition, Writing—reviewing and Editing.
Corresponding authors
Ethics declarations
Conflict of interest
None to declare.
Ethics approval
No potential ethical issues were disclosed.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Jiang, A., Zhang, Z., Qiu, X. et al. Medication-related osteonecrosis of the jaw (MRONJ): a review of pathogenesis hypothesis and therapy strategies. Arch Toxicol 98, 689–708 (2024). https://doi.org/10.1007/s00204-023-03653-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-023-03653-7